Hologic cut to Hold at Argus amid slower mammography equipment sales

Argus downgraded Hologic (HOLX) to Hold from Buy. The firm is citing a higher risk to the management’s FY25 outlook as the company has reduced its revenue guidance due to slower sales of mammography capital equipment, the analyst tells investors in a research note. Argus further notes risks from disruption to AIDS-prevention work as USAID funding is halted and from tariffs given that Hologic uses contract manufacturers in Mexico.